About this trial
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential. This research aims to determine the long-term immune response after administration of one dose of Bio TCV and PQed TCV vaccines in the population in Indonesia. Research participants will be taken from research participants who complete the Bio TCV (Typhoid 0319) Phase III clinical trial research included in the Main Study Group I.
Eligibility criteria
Qualifiers
Healthy
Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form.
Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.
Disqualifiers
History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
Trial design
Treatments tested in this trial
- Not listed